Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

NCT03478826 | Recruiting

• 1 other identifier: 17-008088
• Study Type: observational
• Target: 635
• Locations: 1 country
• Sites: 1

Brief Summary

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

Conditions

Interstitial Lung Disease

Keywords

ILD

Outcome Measures

Primary Outcomes (1)

• Future Disease Management

  Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.

  1 visit

Study Arms (3)

ILD

250 patients (male and females \>18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.

Other: ILD

Healthy

100 healthy participants as a control group.

Other: Healthy

Pneumonia

25 patients with pneumonia as a control group.

Other: Pneumonia

Interventions

ILD OTHER

100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis

ILD

Healthy OTHER

100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.

Healthy

Pneumonia OTHER

100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.

Pneumonia

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with a diagnosis of ILD or any fibrotic disease of the lung. A diagnosis of pneumonia and healthy volunteers will also be included as a control group.

You may qualify if:

• Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
• Patients willing to provide written informed consent

You may not qualify if:

• Unwillingness/unable to give blood samples

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group. The repository would be maintained in Dr. Carmona's laboratory in the Thoracic Diseases Research Unit in the Stabile building where all biospecimens will be stored. These samples will be stored in freezers in Dr. Carmona's laboratory space in the Thoracic Diseases Research Unit in the Stabile building for future research.

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases

Study Officials

• Eva M Carmona Porquera, MD, PhD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Stachowitz

CONTACT

507-284-4862; Stachowitz.Michael@mayo.edu

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Medicine, College of Medicine

Study Record Dates

• First Submitted: March 23, 2018
• First Posted: March 27, 2018
• Study Start: August 1, 2018
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2028
• Last Updated: April 29, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)